Eli Lilly and Company (India) has announced a strategic partnership with Apollo Health and Lifestyle and Apollo HealthCo both part of the Apollo Hospitals network to launch a nationwide campaign aimed at boosting awareness and enhancing treatment for obesity and type 2 diabetes, two of India’s most serious public health issues.
According to a press release, the collaboration will extend across more than 200 Apollo clinics and involve 300 healthcare professionals. The initiative will emphasize patient education and improved training for healthcare providers. “We are committed to making a real difference in how obesity and type 2 diabetes are perceived and treated in India,” said Winselow Tucker, President and General Manager of Lilly India.
Earlier this year, Lilly introduced its highly anticipated weight-loss medication, Mounjaro, to the Indian market.
The prevalence of obesity is rapidly increasing across the country. Apollo’s recent “Health of the Nation” report found that 49% of women and 55% of men aged 40-55 are affected. Obesity is a leading risk factor for type 2 diabetes and is associated with over 200 health issues, including heart disease and sleep disorders.
“This partnership represents a long-term commitment to revolutionizing the way obesity and diabetes are managed in India,” said Sangita Reddy, Joint Managing Director of Apollo Hospitals.
The initiative also aims to develop both digital and physical infrastructure to support scalable, technology-driven healthcare solutions. The goal is to establish a model that can be replicated across the country to improve health outcomes and reduce the burden of chronic non-communicable diseases.
